Shares of Achillion Pharmaceuticals (ACHN) - Get Report were sinking nearly 8% during Thursday morning trading following a downgrade of the biopharmaceutical firm's stock at Baird to "Neutral" from "Outperform" with a $5 price target.
CH-447 is Achillion's treatment for patients with untreated paroxysmal nocturnal hemoglobinuria (PNH), which recently completed a Phase 2 study. But, Baird analyst Brian Skorney remains unconvinced it can compete with Soliris, which also treats PNH.
He adds that while PNH data is interesting, he is not "banking on it."
Skorney also believes the potential milestone payments from Johnson & Johnson (JNJ) - Get Report for Hepatitis C treatments justify much of its current valuation. In May, the two companies entered into a collaboration arrangement in which Johnson & Johnson would develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets.
Watch More with TheStreet:
- Who Holds the Biggest Share of Snap?
- Who is the French Billionaire Making a Play for Charter Communications?
- It's Not Just North Korea, This is a Stronger Time for Gold
- Which Cryptocurrency Will Last?